Marcello Stanzione, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Breaks, Double-Stranded | 7 | 2024 | 594 | 1.100 |
Why?
|
| Meiosis | 7 | 2024 | 339 | 0.870 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2022 | 388 | 0.720 |
Why?
|
| Synaptonemal Complex | 2 | 2024 | 26 | 0.640 |
Why?
|
| Cell Cycle Proteins | 6 | 2024 | 3461 | 0.440 |
Why?
|
| Retinoblastoma Protein | 2 | 2022 | 704 | 0.320 |
Why?
|
| Phthalazines | 3 | 2022 | 363 | 0.250 |
Why?
|
| Spermatocytes | 3 | 2019 | 42 | 0.240 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 13096 | 0.220 |
Why?
|
| DNA Replication | 2 | 2022 | 1399 | 0.220 |
Why?
|
| Cytidine Deaminase | 1 | 2023 | 252 | 0.200 |
Why?
|
| Chromatin | 3 | 2022 | 2934 | 0.180 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 382 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3557 | 0.160 |
Why?
|
| Chromosomes, Mammalian | 1 | 2018 | 151 | 0.150 |
Why?
|
| Piperazines | 3 | 2022 | 2491 | 0.140 |
Why?
|
| Recombination, Genetic | 2 | 2024 | 1586 | 0.140 |
Why?
|
| Endodeoxyribonucleases | 1 | 2016 | 166 | 0.130 |
Why?
|
| Antibodies, Bispecific | 1 | 2017 | 164 | 0.120 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 474 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2017 | 671 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2022 | 2969 | 0.110 |
Why?
|
| DNA Damage | 1 | 2022 | 2432 | 0.100 |
Why?
|
| DNA | 2 | 2024 | 7303 | 0.100 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2183 | 0.100 |
Why?
|
| Chromosome Pairing | 2 | 2021 | 47 | 0.090 |
Why?
|
| Zebrafish | 1 | 2021 | 2994 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 4440 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 16687 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 5853 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2018 | 14556 | 0.080 |
Why?
|
| Phosphate-Binding Proteins | 2 | 2018 | 70 | 0.070 |
Why?
|
| Rad51 Recombinase | 2 | 2018 | 189 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 6612 | 0.070 |
Why?
|
| Chromosome Segregation | 2 | 2019 | 236 | 0.070 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2017 | 1628 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2019 | 5021 | 0.070 |
Why?
|
| Animals | 10 | 2024 | 168788 | 0.060 |
Why?
|
| Mice | 8 | 2024 | 81178 | 0.050 |
Why?
|
| E2F1 Transcription Factor | 1 | 2022 | 190 | 0.050 |
Why?
|
| E2F Transcription Factors | 1 | 2022 | 277 | 0.050 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2022 | 102 | 0.050 |
Why?
|
| Pachytene Stage | 1 | 2021 | 3 | 0.050 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2021 | 88 | 0.050 |
Why?
|
| Gametogenesis | 1 | 2021 | 26 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2022 | 317 | 0.050 |
Why?
|
| Sex Chromosomes | 1 | 2021 | 105 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2023 | 695 | 0.040 |
Why?
|
| Meiotic Prophase I | 1 | 2018 | 8 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2021 | 1827 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11493 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2021 | 479 | 0.040 |
Why?
|
| Y Chromosome | 1 | 2019 | 206 | 0.040 |
Why?
|
| Protein Binding | 2 | 2022 | 9392 | 0.040 |
Why?
|
| Gonads | 1 | 2017 | 109 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2022 | 729 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 5169 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 1549 | 0.030 |
Why?
|
| X Chromosome | 1 | 2019 | 815 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2021 | 1004 | 0.030 |
Why?
|
| Autophagy | 1 | 2022 | 1300 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6313 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1269 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2016 | 2256 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 2649 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2023 | 2727 | 0.030 |
Why?
|
| Oocytes | 1 | 2016 | 1187 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2022 | 5867 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2017 | 956 | 0.020 |
Why?
|
| Humans | 6 | 2023 | 744220 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2017 | 1736 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 29784 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 21672 | 0.020 |
Why?
|
| Cell Line | 1 | 2022 | 15999 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2017 | 2924 | 0.020 |
Why?
|
| DNA Repair | 1 | 2016 | 2046 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3523 | 0.020 |
Why?
|
| Male | 6 | 2021 | 350027 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 9735 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16365 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 9647 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10182 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 11368 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9230 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9582 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 21824 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 40992 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23404 | 0.010 |
Why?
|
| Female | 3 | 2021 | 380197 | 0.010 |
Why?
|
| Adult | 2 | 2021 | 214035 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 57768 | 0.010 |
Why?
|
| Child | 1 | 2021 | 77679 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85759 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 63119 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 163253 | 0.000 |
Why?
|
| Middle Aged | 1 | 2019 | 213367 | 0.000 |
Why?
|